	US 12,270,042 B2
	Methods for preventing and treating type II diabetes
Michael Stitzel, Bar Harbor, ME (US)
Assigned to The Jackson Laboratory, Bar Harbor, ME (US)
Appl. No. 16/966,287
Filed by The Jackson Laboratory, Bar Harbor, ME (US)
PCT Filed Jan. 31, 2019, PCT No. PCT/US2019/015958 § 371(c)(1), (2) Date Jul. 30, 2020, PCT Pub. No. WO2019/152590, PCT Pub. Date Aug. 8, 2019.
Claims priority of provisional application 62/666,596, filed on May 3, 2018.
Claims priority of provisional application 62/624,640, filed on Jan. 31, 2018.
Prior Publication US 2020/0370068 A1, Nov. 26, 2020 Prior Publication US 2021/0317473 A9, Oct. 14, 2021
Int. Cl. C12N 15/85 (2006.01); A01K 67/0275 (2024.01); A61K 38/28 (2006.01); C12Q 1/6827 (2018.01); G01N 33/74 (2006.01)

CPC C12N 15/8509 (2013.01) [A01K 67/0275 (2013.01); A61K 38/28 (2013.01); C12Q 1/6827 (2013.01); G01N 33/74 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0362 (2013.01); C12N 2015/8527 (2013.01); C12Q 2600/156 (2013.01)]

4 Claims

1. A mouse comprising homozygous deletions in C2 calcium-dependent domain containing 4A (C2cd4a^−/−) and C2 calcium-dependent domain containing 4B (C2cd4b^−/−), wherein C2cd4a^−/− C2cd4b^−/− cells of the mouse exhibit impaired glucose stimulated insulin secretion (GSIS).